[Mixte community-acquired Legionella pneumophila and Staphylococcus aureus pneumonia].
Bouhaja
B
B
Thabet
H
H
Slim
L
L
Aissa
F
F
Amamou
M
M
Yacoub
M
M
D000328:Adult; D017714:Community-Acquired Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007877:Legionnaires' Disease / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D015242:Ofloxacin / Q000627:therapeutic use; D011023:Pneumonia, Staphylococcal / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D012293:Rifampin / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000302:isolation & purification
D015242:Ofloxacin; D012293:Rifampin
Pneumopathie communautaire mixte à Legionella pneumophila et Staphylococcus aureus.